Table 3 Result of recovery of nabumetone www.selleckchem.com/products/BI6727-Volasertib.html and paracetamol by first-order derivative method Precision The precision of an analytical method was expressed as the percent relative standard deviation and standard error of mean of the series of measurements. It was ascertained by the replicate estimation of standard drugs. It involves intraday and interday precision. For intraday precision, three replicates of the solutions containing 12 ��g/ml of NBM and 12 ��g/ml of PRCM were carried out three times on the same day, and for interday precision, three replicates of the solutions were carried out for the three consecutive days at the same concentration level. Results are summarized in Table 3. Limit of detection and limit of quantitation The detection limit (DL) and the quantitation limit (QL) were calculated on the basis of the standard deviation of the y-intercept and slope: DL = 3.

3 ��/S and QL = 10 ��/S, where �� is the standard deviation of the response and S is the slope of the calibration curve of analyte. The DL and QL values 0.56 and 1.3 for NBM and 0.04 and 0.12 for PRCM showed good precision for the proposed method. One-way analysis of variance test One-way analysis of variance test was performed for the percent mean of intraday and interday precision of NBM and PRCM. The calculated P value was found to be 0.383 and 0.816 for NBM and PRCM, respectively, which is greater than the theoretical P value (P >.05). It shows that there is no statistically significant difference between the intraday and interday precision of NBM and PRCM.

CONCLUSION The developed first-order derivative spectroscopic method proved to be simpler in procedure and produced more accurate results. Hence, the method is effective for the routine analysis of NBM and PRCM in bulk and tablet dosage form. ACKNOWLEDGMENTS The authors gratefully acknowledge the IPCA Laboratories Pvt. Ltd., Ratlam, Gujarat, India, for providing gift sample of nabumetone and paracetamol. The authors are also thankful to Management and Principal Dr. Rajendra S. Bhambar of M.G.V’s Pharmacy College, Panchavati, Nashik for providing necessary facilities and constant support for research work. ��This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.�� Footnotes Source of Support: Nil. Conflict of Interest: None declared.

Paricalcitol hard gelatin capsules contain the active ingredient paricalcitol which is a synthetically manufactured analog of calcitriol, the metabolically active form of vitamin D indicated for the prevention and treatment of secondary hyperparathyroidism in chronic kidney disease. Paricalcitol HG capsule oral administration contains 1, 2 or 4 ��g of paricalcitol. Dacomitinib Use of hard gelatin capsule offers processing convenience in minimizing the hazards of cross-contamination, reduces the need for complex and expensive engineering controls, and assures product uniformity.